https://www.clinicaltrials.gov/study/NCT03666000?term=imugene&rank=1&tab=history&a=16&b=17#version-content-panel
It appears that the Azer Cell study has hit a hurdle. This study has changed from being a phase 1/2a study to a phase 1/1(a) study. The timeline has also blown with primary completion now being 03/2026 from 03/2024 and study completion changing from 06/2024 until 03/2028.
The trial is also now a dose expansion study to evaluate the safety and clinical activity instead of a dose expansion study.
Finally obersarvations are now up to day 720 instead of 28 days.
Does anyone have knowledge of why this occurs? Is it as a a result of toxicity issues?
Media Thread, page-14401
-
- There are more pages in this discussion • 754 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.6¢ | 5.2¢ | $735.1K | 13.70M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 3131146 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 151349 | 3 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |